Clinical Trials Logo

Clinical Trial Summary

In vitro studies have demonstrated that sodium selenite in sufficient concentration and during sufficient time have a high tumoricidal capacity. This is found in many human cell types as leukemia cells, mesothelioma and non-small cell lung cancer cells. A minority of cell lines seem to be resistant. The question from a clinical point of view is: Is it possible with respect to toxicity to administer sodium selenite to patients in sufficient dose and during sufficient time to get responses in patients with cancer? We have performed first part of phase-1 study and found MTD of 10.2 mg/m2 if given as 10 daily infusions during 12 days. We have recorded limited anti-tumor effect in this treatment regimen. However, in vitro data suggest that low concentration of continuous exposure for 51 h is much more effective. Now we are planning to continue the phase-I trial with modified protocol.

More specific:

1. Phase I: Find maximal tolerable dose with continuous infusion

2. Phase II: Use MTD and study responses, if any


Clinical Trial Description

- Patients: With advanced malignant disease, any kind, in which all standard treatment has been tried, but still progression. In sufficient good performance status (ps 0-2)to get more treatment: first selenite and immediately afterwards chemotherapy (since an additive or synergistic effect from selenite and chemotherapy has been found).

- Treatment: We have performed the initial study with sodium selenite i.v. daily, 10 treatments during 2 weeks. The week after that response evaluation and then chemotherapy. In each patient, his or her first line chemotherapy treatment is given, since in vitro studies indicate that selenite might reverse resistance. In the modified protocol, a 2 days continuous infusion will be performed.

- Toxicity evaluation (main criteria in phase I): Meeting a doctor once a week during selenite treatment and before each chemotherapy treatment and at End of treatment. Meeting a nurse each treatment day during selenite treatment. Blood samples for liver, kidney, blood and thyroid values. Plasma samples for selenite concentration during treatment.

- Response evaluation (to be: main criteria in phase II and studied also in phase I): CT scan just before and after selenite treatment and after chemotherapy. From May 2011 FDG-PET-CT-scan just before and after selenite treatment. Cytokeratin and cytokeratin fragments evaluation. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01959438
Study type Interventional
Source Karolinska University Hospital
Contact Ola Brodin, MD, PhD
Phone +46 8 6164344
Email ola.brodin@karolinska.se
Status Recruiting
Phase Phase 1/Phase 2
Start date February 2007
Completion date June 2018

See also
  Status Clinical Trial Phase
Recruiting NCT04691349 - CAR-T for r/r Malignant Tumors in Children Early Phase 1
Recruiting NCT04672473 - Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine Phase 1/Phase 2
Recruiting NCT06080984 - The Application of Novel Oncolytic Virus in Late Stage Solid Tumors Phase 1
Recruiting NCT04991506 - A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02552004 - Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study N/A
Recruiting NCT05280873 - Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP Phase 1
Completed NCT06093945 - Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects Phase 1
Completed NCT05592262 - Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects Phase 1
Completed NCT03012945 - Epidural Anesthesia-analgesia and Long-term Outcome N/A
Recruiting NCT04686682 - A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT06084767 - 68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer N/A
Enrolling by invitation NCT02937246 - Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction N/A
Completed NCT03354741 - Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children N/A
Recruiting NCT03931720 - Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor Phase 1/Phase 2
Completed NCT01906632 - Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy N/A
Recruiting NCT05596344 - Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors
Active, not recruiting NCT04230200 - Prospective Screening Programme for Malignant Tumors
Completed NCT04952766 - Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults Phase 4
Completed NCT04730843 - A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05781555 - A Study of Diffusing Alpha Radiation Therapy for Target Treatments of Malignant Tumors N/A